Company news
Anaptysbio, Inc. (NASDAQ:ANAB) news
Anaptysbio, Inc. news releases on 6ix. Latest, Jan 31, 2024: Anaptys to Present at Guggenheim’s 6th Annual Biotechnology Conference
Press releases — page 2
Anaptys to Present at Guggenheim’s 6th Annual Biotechnology Conference
January 30, 2024
Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals
November 26, 2023
Anaptys Named a BioSpace 2024 Best Places to Work Winner
November 6, 2023
Anaptys Announces Third Quarter 2023 Financial Results and Provides Business Update
November 1, 2023
Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress
October 10, 2023
Anaptys to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event on Wednesday, Oct. 25
October 8, 2023
Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
October 8, 2023
AnaptysBio Announces Appointment of John Orwin as Chairman of the Board of Directors
September 17, 2023
AnaptysBio to Present at the Stifel 2023 Immunology and Inflammation Virtual Summit
September 11, 2023
AnaptysBio Announces Second Quarter 2023 Financial Results and Provides Business Update
August 6, 2023
AnaptysBio- and GSK-Partnered Immuno-Oncology Agent JEMPERLI (dostarlimab-gxly) plus Chemotherapy Approved in the U.S. for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer
July 30, 2023
AnaptysBio Announces Participation in Upcoming Investor Conferences
May 29, 2023
AnaptysBio Announces First Quarter 2023 Financial Results and Provides Pipeline Update
May 10, 2023
AnaptysBio Announces British Journal of Dermatology Publication of Imsidolimab (IL-36R) Previously Reported Phase 2 GALLOP Data in Generalized Pustular Psoriasis (GPP)
May 1, 2023
AnaptysBio Announces Appointment of Rita Jain, M.D., to Board of Directors
April 5, 2023
AnaptysBio- and GSK-partnered immuno-oncology agent Jemperli (dostarlimab-gxly) plus chemotherapy demonstrates statistically significant and clinically meaningful improvement in progression-free survival for the treatment of primary advanced or recurr...
March 26, 2023
AnaptysBio Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
February 28, 2023
AnaptysBio to Participate at the Cowen and Company 43rd Annual Health Care Conference
February 26, 2023
AnaptysBio Announces Stock Repurchase Plan
January 12, 2023
AnaptysBio Announces Portfolio Update Across Best-in-Class Immune Cell Modulating Antibodies
January 4, 2023
AnaptysBio- and GSK-partnered immuno-oncology agent JEMPERLI (dostarlimab-gxly) meets primary endpoint in Phase 3 RUBY trial in primary advanced or recurrent endometrial cancer
December 1, 2022
AnaptysBio to Participate at the Piper Sandler 34th Annual Healthcare Conference
November 20, 2022
AnaptysBio to Participate in Upcoming November Investor Conferences
November 8, 2022
AnaptysBio Announces Third Quarter 2022 Financial Results and Provides Pipeline Update
November 7, 2022
AnaptysBio and GSK-partnered immuno-oncology agents JEMPERLI (dostarlimab-gxly) and cobolimab show positive progress in two separate non-small cell lung cancer trials
October 4, 2022
AnaptysBio Announces Sale of Zejula Royalties for Up To $45 Million
September 11, 2022
AnaptysBio Reports HARP Phase 2 Top-Line Data of Imsidolimab in Moderate-to-Severe Hidradenitis Suppurativa
August 30, 2022
AnaptysBio Announces Second Quarter 2022 Financial Results and Provides Pipeline Update
August 7, 2022
AnaptysBio to Participate at the 2022 Wedbush PacGrow Healthcare Virtual Conference
August 4, 2022
AnaptysBio to Participate at the 2022 Jefferies Healthcare Conference
June 1, 2022
AnaptysBio Announces First Quarter 2022 Financial Results and Provides Pipeline Update
May 3, 2022
AnaptysBio Announces Positive ANB032 (anti-BTLA agonist) Top-Line Phase 1 Data and Provides Pipeline Updates
April 26, 2022
AnaptysBio Appoints Daniel Faga As Interim Chief Executive Officer
March 20, 2022
AnaptysBio Reports Imsidolimab ACORN Phase 2 Clinical Trial Data in Moderate-to-Severe Acne
March 13, 2022
AnaptysBio Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Pipeline Update
March 6, 2022
AnaptysBio To Present at the 40th Annual J.P. Morgan Healthcare Conference
January 4, 2022
AnaptysBio Announces Appointment of Daniel Faga to Board of Directors
November 28, 2021
AnaptysBio To Present at the 2021 Jefferies London Healthcare Conference
November 14, 2021
AnaptysBio Announces Positive Rosnilimab Healthy Volunteer Phase 1 Top-Line Data
November 14, 2021
AnaptysBio Announces Third Quarter 2021 Financial Results and Provides Pipeline Updates
November 3, 2021
AnaptysBio Announces Agreement to Monetize Portion of JEMPERLI Royalties for $250 Million with Sagard
October 24, 2021
AnaptysBio Presents Updated Data From Imsidolimab Phase 2 GALLOP Trial in Generalized Pustular Psoriasis
October 1, 2021
AnaptysBio to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
September 8, 2021
FDA Grants Accelerated Approval of JEMPERLI (dostarlimab-gxly) for dMMR Recurrent or Advanced Solid Tumors
August 16, 2021
AnaptysBio Announces Second Quarter 2021 Financial Results and Provides Pipeline Updates
August 8, 2021
AnaptysBio to Present at the 2021 Jefferies Virtual Healthcare Conference
May 26, 2021
AnaptysBio Announces First Quarter 2021 Financial Results and Provides Pipeline Updates
May 3, 2021
AnaptysBio Announces Appointment of Oleg Nodelman to Board of Directors
April 11, 2021
AnaptysBio Reports Imsidolimab POPLAR Phase 2 Clinical Trial in Moderate-to-Severe Palmoplantar Pustulosis (PPP) Did Not Meet Primary Endpoint
March 7, 2021
AnaptysBio Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Pipeline Updates
February 24, 2021